PDCD1 and non-small cell lung carcinoma: In clinical practice, for patients with advanced NSCLC with high PD-L1 expression (TPS ≥ 50), single agent first-line treatment with pembrolizumab, an anti-PD-1 antibody, is recommended as the standard treatment of care15.